Literature DB >> 10383914

Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro.

E A Hanna1, S Umhauer, S L Roshong, M P Piechocki, M J Fernstrom, J D Fanning, R J Ruch.   

Abstract

Gap junctional intercellular communication (GJIC) and the expression of gap junction proteins (connexins) are frequently decreased in neoplastic cells and have been increased by cAMP and retinoids. GJIC and connexin expression were investigated in early passage normal human ovarian surface epithelial (HOSE) cells, human ovarian adenocarcinoma cell lines (CaOV-3, NIH:OVCAR-3, SK-OV-3 and SW626) and surgical specimens of human serous cystadenocarcinomas. We hypothesized that GJIC and connexin expression would be decreased in neoplastic cells and would be increased by cAMP and retinoic acid. Cultured HOSE cells exhibited extensive fluorescent dye-coupling and connexin43 (Cx43) expression; other connexins were not detected. The ovarian adenocarcinoma cell lines had little dye-coupling or connexin expression. Deletions and rearrangements of the Cx43 gene were not detected by Southern blotting in the carcinoma lines. N6, 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate and all-trans-retinoic acid inhibited cell proliferation, but did not enhance GJIC or Cx43 expression. Surface epithelial cells of benign ovaries expressed Cx43, but this expression was barely detectable in ovarian serous cystadenocarcinomas. Thus, normal HOSE cells had extensive GJIC and Cx43 expression whereas ovarian carcinoma cells had less and cAMP and retinoic acid did not change these, although both agents inhibited cell growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383914     DOI: 10.1093/carcin/20.7.1369

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Changes in connexin43 expression and localization during pancreatic cancer progression.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  J Membr Biol       Date:  2012-06-23       Impact factor: 1.843

2.  Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model.

Authors:  Paul C Roberts; Emilio P Mottillo; Andrea C Baxa; Henry H Q Heng; Nicole Doyon-Reale; Lucie Gregoire; Wayne D Lancaster; Raja Rabah; Eva M Schmelz
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

Review 3.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Relationship between the expression of connexin43 and bystander effect of suicide gene therapy in ovarian cancer.

Authors:  Ali Zhang; Quansheng Wang; Zhiqiang Han; Sufang Wu; Gang Chen; Jun Li; Guoning Liao; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Altered tumor biology and tumorigenesis in irradiated and chemical carcinogen-treated single and combined connexin32/p27Kip1-deficient mice.

Authors:  Timothy J King; Paul D Lampe
Journal:  Cell Commun Adhes       Date:  2005 Jul-Dec

6.  A Gap Junction Protein, Inx2, Modulates Calcium Flux to Specify Border Cell Fate during Drosophila oogenesis.

Authors:  Aresh Sahu; Ritabrata Ghosh; Girish Deshpande; Mohit Prasad
Journal:  PLoS Genet       Date:  2017-01-23       Impact factor: 5.917

7.  Kca3.1 Activation Via P2y2 Purinergic Receptors Promotes Human Ovarian Cancer Cell (Skov-3) Migration.

Authors:  L Robles-Martínez; E Garay; M G Martel-Gallegos; A Cisneros-Mejorado; D Pérez-Montiel; A Lara; R O Arellano
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

8.  Bisphenol S enhances gap junction intercellular communication in ovarian theca cells.

Authors:  Jeremy Gingrich; Yong Pu; Brad L Upham; Madeline Hulse; Sarah Pearl; Denny Martin; Anita Avery; Almudena Veiga-Lopez
Journal:  Chemosphere       Date:  2020-09-14       Impact factor: 7.086

9.  Multilayer spheroids to quantify drug uptake and diffusion in 3D.

Authors:  Toni-Marie Achilli; Stephanie McCalla; Julia Meyer; Anubhav Tripathi; Jeffrey R Morgan
Journal:  Mol Pharm       Date:  2014-04-02       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.